Phase 3 Rheumatoid Arthritis Trial, Recruiting NCT07404865 Sponsor: Vor Biopharma Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Phase 3 Rheumatoid Arthritis Trial, Recruiting

NCT07404865
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (inclusive)
  • You have been diagnosed with primary Sjögren's Syndrome according to recognised international guidelines (from 2016)
  • Your Sjögren's Syndrome is considered active enough to meet a minimum disease activity score of 5 on a specific measurement tool called the ESSDAI (confirm with trial site)
  • A blood test shows you carry specific antibodies linked to Sjögren's Syndrome, known as SSA/Ro antibodies

Who may not be able to join:

  • You have another systemic autoimmune disease (such as rheumatoid arthritis, lupus, or systemic sclerosis) that better explains most of your symptoms, meaning your Sjögren's is considered secondary rather than primary
  • You have another autoimmune or inflammatory condition (such as inflammatory bowel disease or gout) that could make it difficult to measure how well your Sjögren's responds to treatment
  • You have severe fibromyalgia (a chronic pain condition) that could interfere with measuring how your Sjögren's Syndrome responds to treatment
  • Your Sjögren's Syndrome is causing serious, life-threatening complications to your organs at the time of screening, as judged by the study doctor
  • You have a significant, poorly controlled medical condition in any part of your body unrelated to Sjögren's Syndrome (such as poorly controlled asthma, heart disease, high blood pressure, or major depression) that the study doctor feels would make participation unsafe

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 6176556580

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Vor Biopharma
Registry
ClinicalTrials.gov
Start date
26 February 2026
Est. completion
1 December 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

To evaluate the efficacy of telitacicept versus placebo at Week 48 in the change from baseline in the EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at Week 48.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov